Automated PD-L1 scoring using artificial intelligence in head and neck squamous cell carcinoma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
Rheinisch-Westfälische Technische Hochschule Aachen, Dissertation, 2022
- Schlagwort
-
Squamous cell carcinoma
Head
Artificial intelligence
Neck
Basel
- Ereignis
-
Veröffentlichung
- (wo)
-
Aachen
- (wer)
-
Universitätsbibliothek der RWTH Aachen
- (wann)
-
2022
- Urheber
- Beteiligte Personen und Organisationen
-
Knüchel-Clarke, Ruth
Truhn, Daniel
- DOI
-
10.18154/RWTH-2022-04697
- URN
-
urn:nbn:de:101:1-2022062011320414243683
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:32 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Puladi, Behrus
- Knüchel-Clarke, Ruth
- Truhn, Daniel
- Universitätsbibliothek der RWTH Aachen
Entstanden
- 2022
Ähnliche Objekte (12)
Optimized PD-L1 scoring of gastric cancer
Automated PD-L1 Scoring Using Artificial Intelligence in Head and Neck Squamous Cell Carcinoma
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Integration of Spatial PD-L1 Expression with the Tumor Immune Microenvironment Outperforms Standard PD-L1 Scoring in Outcome Prediction of Urothelial Cancer Patients
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
PD-L1 expression correlated with p53 expression in oral squamous cell carcinoma
Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation
Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
Regulatory mechanisms of PD-1/PD-L1 in cancers
Optimized PD-L1 scoring of gastric cancer
Automated PD-L1 Scoring Using Artificial Intelligence in Head and Neck Squamous Cell Carcinoma
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Integration of Spatial PD-L1 Expression with the Tumor Immune Microenvironment Outperforms Standard PD-L1 Scoring in Outcome Prediction of Urothelial Cancer Patients
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
PD-L1 expression correlated with p53 expression in oral squamous cell carcinoma
Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation
Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
Regulatory mechanisms of PD-1/PD-L1 in cancers
Optimized PD-L1 scoring of gastric cancer
Automated PD-L1 Scoring Using Artificial Intelligence in Head and Neck Squamous Cell Carcinoma
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Integration of Spatial PD-L1 Expression with the Tumor Immune Microenvironment Outperforms Standard PD-L1 Scoring in Outcome Prediction of Urothelial Cancer Patients
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
PD-L1 expression correlated with p53 expression in oral squamous cell carcinoma
Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation
Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?